⌘K
Loading ticker…
As of 2026-08-24, GT Biopharma Inc. Common Stock (GTBP) has a 3-month relative strength percentile of 14 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 34. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.4%, relative volume 1.45×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
GTBP is in a stage 4 downtrend, week 7. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -18.4% / -38.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
GTBP appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $184K notional.
Held by 1 ETFs · $184K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $184K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GTBP Jan avg: -19.06% median: -19.14% win: 0% σ: 6.97% n: 4 2022-04-12 → 2026-07-31 | GTBP Feb avg: -15.68% median: -20.25% win: 25% σ: 16.61% n: 4 2022-04-12 → 2026-07-31 | GTBP Mar avg: -9.78% median: -12.14% win: 25% σ: 10.68% n: 4 2022-04-12 → 2026-07-31 | GTBP Apr avg: -17.72% median: -24.48% win: 20% σ: 18.47% n: 5 2022-04-12 → 2026-07-31 | GTBP May avg: 15.36% median: 25.00% win: 80% σ: 35.85% n: 5 2022-04-12 → 2026-07-31 | GTBP Jun avg: 12.70% median: 8.33% win: 80% σ: 26.73% n: 5 2022-04-12 → 2026-07-31 | GTBP Jul avg: -21.95% median: -11.86% win: 0% σ: 20.67% n: 5 2022-04-12 → 2026-07-31 | GTBP Aug avg: -21.11% median: -14.79% win: 0% σ: 19.78% n: 4 2022-04-12 → 2026-07-31 (current) | GTBP Sep avg: -17.31% median: -19.70% win: 25% σ: 20.90% n: 4 2022-04-12 → 2026-07-31 | GTBP Oct avg: 10.82% median: 6.31% win: 100% σ: 11.11% n: 4 2022-04-12 → 2026-07-31 | GTBP Nov avg: -0.44% median: -8.03% win: 25% σ: 17.89% n: 4 2022-04-12 → 2026-07-31 | GTBP Dec avg: -5.53% median: 4.15% win: 50% σ: 28.03% n: 4 2022-04-12 → 2026-07-31 |